SCHEMBL10237396

SCHEMBL10237396

CC(=O)Oc1ccc(Oc2ccc(Br)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
MAPT P10636 6/20 0.52
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
RAB9A P51151 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
ELANE P08246 2/20 0.50
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
SRD5A2 P31213 1/20 0.49
HSD17B10 Q99714 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154474 0.94 LMNA (0.64) LMNAMAPTPOLBPKMRAB9A
SCHEMBL11579928 0.91 LMNA (0.61) LMNAMAPTPOLBPKMRAB9A
SCHEMBL28599109 0.91 LMNA (0.61) LMNAMAPTPOLBPKMRAB9A
SCHEMBL5027571 0.89 LMNA (0.70) LMNAMAPTPOLBPKMRAB9A
SCHEMBL9760958 0.89 LMNA (0.70) LMNAMAPTPOLBPKMRAB9A
SCHEMBL177352 0.88 HSD17B10 (0.63) LMNAMAPTPOLBPKMRAB9A
SCHEMBL21629498 0.86 ELANE (0.69) LMNAMAPTPOLBPKMRAB9A
SCHEMBL9341842 0.82 MAPT (0.69) LMNAMAPTPOLBPKMRAB9A
SCHEMBL9341839 0.82 MAPT (0.69) LMNAMAPTPOLBPKMRAB9A
SCHEMBL269329 0.82 LMNA (0.80) LMNAMAPTPOLBPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases MMP9, MMP1, MMP2 LMNA 672/4885MAPT 4017/4885POLB 1757/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 LMNA 358/4885MAPT 4253/4885POLB 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.